Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to -$421.7 million.

  • Corcept Therapeutics' Enterprise Value fell 1087.12% to -$421.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$421.7 million, marking a year-over-year decrease of 1087.12%. This contributed to the annual value of -$383.3 million for FY2024, which is 410.43% down from last year.
  • As of Q3 2025, Corcept Therapeutics' Enterprise Value stood at -$421.7 million, which was down 1087.12% from -$342.2 million recorded in Q2 2025.
  • Corcept Therapeutics' 5-year Enterprise Value high stood at -$223.5 million for Q4 2021, and its period low was -$473.2 million during Q2 2024.
  • Over the past 5 years, Corcept Therapeutics' median Enterprise Value value was -$370.1 million (recorded in 2022), while the average stood at -$376.7 million.
  • Per our database at Business Quant, Corcept Therapeutics' Enterprise Value skyrocketed by 4927.68% in 2021 and then crashed by 9311.16% in 2022.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Enterprise Value stood at -$223.5 million in 2021, then tumbled by 93.11% to -$431.7 million in 2022, then grew by 14.7% to -$368.2 million in 2023, then decreased by 4.1% to -$383.3 million in 2024, then fell by 10.0% to -$421.7 million in 2025.
  • Its Enterprise Value stands at -$421.7 million for Q3 2025, versus -$342.2 million for Q2 2025 and -$322.8 million for Q1 2025.